Company intelligence / Profile preview

KBP Brands

Princeton, New Jersey, United Stateskbpbrands.com ↗

Ownership: Private
Employees: ~47
Development stage: Commercial

Overview

KBP Biosciences develops small molecule drugs targeting major organ systems—lung, heart, kidney—as well as infectious and immunological diseases. Its pipeline includes clinical-stage assets such as zifanocycline (Phase 1), with previous late-stage development of ocedurenone for chronic kidney disease now discontinued. The company leverages proprietary microbial banks and focuses on both discovery and clinical development.

Therapeutic areas: NephrologyMetabolic DisordersPulmonologyEndocrinologyImmunologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on KBP Brands.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBP Brands.

Explore the full profile